NOVO NORDISK A/S-B (NOV.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:NOV • DK0062498333

41.245 EUR
+0.35 (+0.86%)
Last: Feb 12, 2026, 12:57 PM
Fundamental Rating

6

Taking everything into account, NOV scores 6 out of 10 in our fundamental rating. NOV was compared to 55 industry peers in the Pharmaceuticals industry. While NOV has a great profitability rating, there are quite some concerns on its financial health. NOV is not valued too expensively and it also shows a decent growth rate. Finally NOV also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year NOV was profitable.
  • In the past year NOV had a positive cash flow from operations.
  • Each year in the past 5 years NOV has been profitable.
  • In the past 5 years NOV always reported a positive cash flow from operatings.
NOV.DE Yearly Net Income VS EBIT VS OCF VS FCFNOV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

1.2 Ratios

  • NOV's Return On Assets of 18.87% is amongst the best of the industry. NOV outperforms 98.18% of its industry peers.
  • With an excellent Return On Equity value of 52.79%, NOV belongs to the best of the industry, outperforming 94.55% of the companies in the same industry.
  • NOV's Return On Invested Capital of 30.79% is amongst the best of the industry. NOV outperforms 98.18% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for NOV is significantly above the industry average of 14.21%.
  • The last Return On Invested Capital (30.79%) for NOV is well below the 3 year average (43.61%), which needs to be investigated, but indicates that NOV had better years and this may not be a problem.
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROIC 30.79%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
NOV.DE Yearly ROA, ROE, ROICNOV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • The Profit Margin of NOV (33.14%) is better than 100.00% of its industry peers.
  • In the last couple of years the Profit Margin of NOV has remained more or less at the same level.
  • NOV has a better Operating Margin (41.30%) than 94.55% of its industry peers.
  • In the last couple of years the Operating Margin of NOV has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 80.98%, NOV belongs to the top of the industry, outperforming 83.64% of the companies in the same industry.
  • NOV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
NOV.DE Yearly Profit, Operating, Gross MarginsNOV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

3

2. Health

2.1 Basic Checks

  • NOV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for NOV remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, NOV has more shares outstanding
  • The debt/assets ratio for NOV is higher compared to a year ago.
NOV.DE Yearly Shares OutstandingNOV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B
NOV.DE Yearly Total Debt VS Total AssetsNOV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100B 200B 300B 400B 500B

2.2 Solvency

  • An Altman-Z score of 4.08 indicates that NOV is not in any danger for bankruptcy at the moment.
  • NOV has a Altman-Z score (4.08) which is comparable to the rest of the industry.
  • NOV has a debt to FCF ratio of 4.52. This is a neutral value as NOV would need 4.52 years to pay back of all of its debts.
  • NOV's Debt to FCF ratio of 4.52 is in line compared to the rest of the industry. NOV outperforms 58.18% of its industry peers.
  • A Debt/Equity ratio of 0.61 indicates that NOV is somewhat dependend on debt financing.
  • NOV has a Debt to Equity ratio of 0.61. This is comparable to the rest of the industry: NOV outperforms 52.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Altman-Z 4.08
ROIC/WACC4.58
WACC6.72%
NOV.DE Yearly LT Debt VS Equity VS FCFNOV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.3 Liquidity

  • A Current Ratio of 0.80 indicates that NOV may have some problems paying its short term obligations.
  • With a Current ratio value of 0.80, NOV is not doing good in the industry: 87.27% of the companies in the same industry are doing better.
  • NOV has a Quick Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.57, NOV is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.57
NOV.DE Yearly Current Assets VS Current LiabilitesNOV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B 200B

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 3.01% over the past year.
  • Measured over the past years, NOV shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.95% on average per year.
  • The Revenue has been growing slightly by 6.43% in the past year.
  • NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.48% yearly.
EPS 1Y (TTM)3.01%
EPS 3Y24.02%
EPS 5Y20.95%
EPS Q2Q%-0.29%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-8.98%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.65% on average over the next years.
  • NOV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.90% yearly.
EPS Next Y-2.28%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
EPS Next 5Y6.65%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y5.9%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NOV.DE Yearly Revenue VS EstimatesNOV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100B 200B 300B 400B
NOV.DE Yearly EPS VS EstimatesNOV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.22, which indicates a correct valuation of NOV.
  • 76.36% of the companies in the same industry are more expensive than NOV, based on the Price/Earnings ratio.
  • NOV is valuated cheaply when we compare the Price/Earnings ratio to 28.18, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 13.52, NOV is valued correctly.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NOV indicates a somewhat cheap valuation: NOV is cheaper than 76.36% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. NOV is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 13.22
Fwd PE 13.52
NOV.DE Price Earnings VS Forward Price EarningsNOV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NOV is valued a bit cheaper than 76.36% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, NOV is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 47.22
EV/EBITDA 9.76
NOV.DE Per share dataNOV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • NOV has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.63
EPS Next 2Y1.88%
EPS Next 3Y6.76%

7

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 4.17%, NOV is a good candidate for dividend investing.
  • NOV's Dividend Yield is rather good when compared to the industry average which is at 1.94. NOV pays more dividend than 83.64% of the companies in the same industry.
  • NOV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 4.17%

5.2 History

  • The dividend of NOV is nicely growing with an annual growth rate of 19.05%!
Dividend Growth(5Y)19.05%
Div Incr Years0
Div Non Decr Years0
NOV.DE Yearly Dividends per shareNOV.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2 4 6 8 10

5.3 Sustainability

  • 50.53% of the earnings are spent on dividend by NOV. This is a bit on the high side, but may be sustainable.
  • The dividend of NOV is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
NOV.DE Yearly Income VS Free CF VS DividendNOV.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B
NOV.DE Dividend Payout.NOV.DE Dividend Payout, showing the Payout Ratio.NOV.DE Dividend Payout.PayoutRetained Earnings

NOVO NORDISK A/S-B

FRA:NOV (2/12/2026, 12:57:00 PM)

41.245

+0.35 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)05-05
Inst Owners33.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap183.27B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts71.88
Price Target54.04 (31.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.17%
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.64%
Min EPS beat(2)-7.04%
Max EPS beat(2)5.77%
EPS beat(4)2
Avg EPS beat(4)0.38%
Min EPS beat(4)-7.04%
Max EPS beat(4)5.77%
EPS beat(8)5
Avg EPS beat(8)1.56%
EPS beat(12)8
Avg EPS beat(12)1.83%
EPS beat(16)11
Avg EPS beat(16)1.95%
Revenue beat(2)0
Avg Revenue beat(2)-1.88%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.58%
Revenue beat(4)0
Avg Revenue beat(4)-1.33%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)-0.44%
Revenue beat(8)2
Avg Revenue beat(8)-0.05%
Revenue beat(12)5
Avg Revenue beat(12)0.38%
Revenue beat(16)8
Avg Revenue beat(16)0.73%
PT rev (1m)-1.65%
PT rev (3m)-11.79%
EPS NQ rev (1m)-5.7%
EPS NQ rev (3m)-11.39%
EPS NY rev (1m)-1.1%
EPS NY rev (3m)-11.16%
Revenue NQ rev (1m)-21.29%
Revenue NQ rev (3m)49.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.82%
Valuation
Industry RankSector Rank
PE 13.22
Fwd PE 13.52
P/S 4.43
P/FCF 47.22
P/OCF 11.49
P/B 7.05
P/tB 21.39
EV/EBITDA 9.76
EPS(TTM)3.12
EY7.56%
EPS(NY)3.05
Fwd EY7.39%
FCF(TTM)0.87
FCFY2.12%
OCF(TTM)3.59
OCFY8.7%
SpS9.31
BVpS5.85
TBVpS1.93
PEG (NY)N/A
PEG (5Y)0.63
Graham Number20.26
Profitability
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROCE 39.01%
ROIC 30.79%
ROICexc 33.56%
ROICexgc 59.2%
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
FCFM 9.38%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Debt/EBITDA 0.79
Cap/Depr 409.94%
Cap/Sales 29.16%
Interest Coverage 37.34
Cash Conversion 79.59%
Profit Quality 28.3%
Current Ratio 0.8
Quick Ratio 0.57
Altman-Z 4.08
F-Score5
WACC6.72%
ROIC/WACC4.58
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)3.01%
EPS 3Y24.02%
EPS 5Y20.95%
EPS Q2Q%-0.29%
EPS Next Y-2.28%
EPS Next 2Y1.88%
EPS Next 3Y6.76%
EPS Next 5Y6.65%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-8.98%
Revenue Next Year0.24%
Revenue Next 2Y3.47%
Revenue Next 3Y6.32%
Revenue Next 5Y5.9%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year13.84%
EBIT Next 3Y11.7%
EBIT Next 5Y9.7%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%

NOVO NORDISK A/S-B / NOV.DE FAQ

What is the fundamental rating for NOV stock?

ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.


Can you provide the valuation status for NOVO NORDISK A/S-B?

ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.


What is the profitability of NOV stock?

NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.


Can you provide the expected EPS growth for NOV stock?

The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to decline by -2.28% in the next year.


Is the dividend of NOVO NORDISK A/S-B sustainable?

The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.